This study is testing if Tirzepatide, a medication given as weekly injections, can help people with obesity and Atrial Fibrillation (AFib) improve their AFib. Researchers believe that the weight loss from Tirzepatide could lead to better control and fewer symptoms of AFib. You could be eligible if you are between 18 and 80 years old, have a Body Mass Index (BMI) between 27 and 60, and have symptomatic AFib documented by an ECG or monitor. The study aims to enroll 100 participants and will measure how much AFib you experience over 12 months to see if Tirzepatide is effective.

Study design

This is a randomized, double-blind study, meaning participants are randomly assigned to receive either Tirzepatide or a placebo, and neither you nor the researchers will know which you are receiving. The study plans to enroll 100 participants.

What's involved

Participants will receive weekly subcutaneous injections of either Tirzepatide or placebo, with doses increasing over 12 weeks. You will be followed for 12 months, and your AFib will be monitored using an FDA-approved event monitor.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 12 months after starting the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.